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Revisiting Sutton’s Law in
ST-Segment Elevation Myocardial Infarction*Eric Larose, DVM, MDC ompared with complete revascularization(CR), incomplete revascularization of coro-nary artery disease is associated with a
greater risk of future cardiac events, including death
(1). It has long been held, however, that primary
percutaneous coronary intervention (PCI) for ST-
segment elevation myocardial infarction (STEMI)
should limit itself to the infarct-related artery (IRA)
only. Simply stated, because “that’s where the lesion
is,” to paraphrase Willie Suttony (2). This recommen-
dation makes sense, because an unforeseen complica-
tion during intervention in the non-IRA territory
would add insult to injury by transforming a single-
territory event into a multiple-territory one: at the
very least, more widespread myocardial stunning,
and at the worst, greater myocardial necrosis at
a time of looming instability during an acute syn-
drome. It simply does not appear reasonable to
take this added risk. After all, the decision to pro-
ceed with multiple-vessel coronary angioplasty in
chronic coronary artery disease is typically multi-
faceted, taking into consideration symptom burden,
response to medical therapy, ischemia burden, car-
diac function, coronary anatomy, lesion features,
and comorbidity/overall risk.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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yWhen asked by a judge why he robbed banks, Willie Sutton reportedly
replied: “Because that’s where the money is!” Although later refuted by
Sutton himself, the diagnostic strategy of going for the obvious is referred
to as Sutton’s law, on occasion leading to cognitive error.In the setting of primary PCI, most of these fea-
tures are unknown, and the decision to perform
multiple-vessel PCI becomes guided primarily by
coronary anatomy and lesion features. Although
counterintuitive and at odds with the thoughtful
approach usually mandated by coronary intervention,
the different nature of an acute coronary syndrome
as compared with stable disease may warrant a
different approach. In effect, patients with STEMI
are at a greater risk of suffering from an additional
myocardial infarction and events (3). Furthermore,
post-infarction cardiac remodelling impacts a slew
of key prognostic determinants including function,
volumes, and arrhythmogenic milieu. Although
remodelling depends greatly on successful revascu-
larization of the IRA, the ﬁeld is increasingly recog-
nizing the contribution of neighboring vessels
through collateralization of the IRA but also through
the inﬂuence non-IRA territories have on global
cardiac geometry.
The historical aversion to multiple-vessel PCI in
STEMI rests, not only on common sense, but also on
observational studies. In one such analysis, the per-
formance of multivessel PCI at the time of primary PCI
was associated with greater in-hospital mortality
compared to primary PCI of the IRA only when unsta-
ble patients were excluded (mortality differences were
lost at 24 and 42 months) (4). However, some inter-
esting additional ﬁndings emerged as staged PCI (non-
IRA PCI performed in a second procedure within 60
days) led to decreased mortality at 12 months
compared with PCI of the IRA alone (mortality differ-
ences also lost at further time points). Potential mor-
tality beneﬁt of staged multivessel PCI for STEMI was
recently conﬁrmed in a second contemporary registry
(5). Such key studies opened the door to newer ques-
tions surrounding the timing of multivessel PCI for
STEMI. Large meta-analyses supplemented these
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staged multivessel PCI in STEMI could reduce mor-
tality, as long as primary PCI focused only on the IRA,
and non-IRA vessel intervention was performed at
a second time (whether in-hospital or following
discharge) (6). Faced with such evidence suggesting
potential beneﬁt, the question of multivessel PCI in
STEMI was cited as an important area of research by
the 2013 ACCF/AHA Guideline for the Management of
STEMI (7).
Since 2013, randomized controlled trials have begun
to better inform decisions towards multivessel PCI in
STEMI. The PRAMI (Preventive Angioplasty
in Myocardial Infarction) study reported data from
465 patients with STEMI with multivessel stenosis
(deﬁned as 50% diameter stenosis visually); ran-
domization was performed following successful IRA
angioplasty, where one-half were randomized to IRA
PCI only, and one-half to immediate CR (8). Over 2
years follow-up, the CR strategy signiﬁcantly reduced
cardiac death and nonfatal infarction (number needed
to treat [NNT] of 14) and combined cardiac death,
nonfatal infarction, and refractory angina (NNT 7). The
CvLPRIT trial studied 296 patients with STEMI with
multivessel stenosis; randomization was performed
following angiography but before IRA angioplasty,
where one-half underwent IRA PCI only, and one-half
had non-IRA PCI performed preferentially during the
same procedure, but at the very least during the same
hospitalization (9). CR led to a signiﬁcant reduction of
combined all-cause mortality, nonfatal infarction,
heart failure, and ischemia-driven revascularization
(NNT 9) at median follow-up of 1 year.SEE PAGE 2713In this issue of the Journal, McCann et al. (10)
further examine the impact of multivessel versus
IRA-only PCI in the setting of STEMI. They perform
cardiovascular magnetic resonance (CMR) to compare
early infarct characteristics, late infarct characteris-
tics, and late ischemic burden in a sample of the
CvLPRIT (Complete Versus Lesion-Only Primary PCI
Pilot Study) population. The role of CMR here is
unique in providing highly detailed infarct charac-
teristics that were previously inaccessible: Necrosis
size is now measured with greater precision and with
a much lower limit for detection compared with
earlier imaging modalities, and the precise mapping
of infarct distribution reveals non-IRA infarcts that
were before ignored by enzyme rise alone. The
ﬁnding that total infarct size did not differ between
CR and IRA-only PCI is reassuring to those who
were concerned that multivessel PCI may increase
myocardial necrosis, either in territories remotefrom the STEMI by distal embolization or main vessel/
side-branch compromise, or in the STEMI territory
itself by compromise of collateral branches. Arguably,
the strongest predictor of major adverse cardiovas-
cular events following STEMI has repeatedly been
shown to be infarct size by CMR. CMR has previously
informed us on periprocedural injury in PCI by iden-
tifying as little as 1% to 2% necrosis, and the current
study reports similarly impressive reliability. Keeping
this in mind, McCann et al. (10) suggest that there
may be a trade-off when performing CR for STEMI,
because a greater percentage of patients presented
multiple-territory acute necrosis (CR 17.1% vs. IRA-
only 4.8%, p ¼ 0.004). Although the size of such
acute non-IRA infarcts was small (CR 2.5% vs. IRA-
only 2.1% of LV mass, p ¼ 0.004), prior studies
suggest that even so-called “small” infarcts may
have important effects on malignant arrhythmia and
death. Despite these impactful short-term ﬁndings,
an important feature of the current study was to
perform follow-up CMR, conﬁrming that total ne-
crosis size remained similar for CR versus IRA-only
at 9 months. The apparent discordance between an
increased percentage of multiple territory infarcts
and the absence of increase in total infarct size
remains to be explained; because there is little
mechanistic evidence to support such a discrepancy,
these ﬁndings would beneﬁt from corroboration in a
larger sample. Furthermore, although the presumed
beneﬁt of CR has long been decreased ischemic
burden, this study fails to identify any difference in
residual ischemic burden between CR and IRA-only
at 9 months. Such unexpected ﬁndings highlight
important gaps in our knowledge and the impor-
tance of future trials to better inform clinical
decisions.
Clinicians are looking forward to clarity on: 1)
whether multiple-vessel PCI during STEMI may
beneﬁt speciﬁc subpopulations and not others; 2)
what the optimal timing for intervention on the non-
IRA vessel(s) may be; 3) whether speciﬁc interven-
tional strategies, devices, and medications should be
favored; and 4) whether lesion characteristics help
inform the decision, for instance, whether ischemia
testing—either during the index procedure by frac-
tional ﬂow reserve, or early after initial IRA-only
PCI by timely noninvasive imaging—may guide
tailored revascularization of non-IRAs where residual
ischemia remains. Among current ongoing efforts, the
international multicenter COMPLETE (Complete vs.
Culprit-Only Revascularization to Treat Multi-Vessel
Disease After Primary PCI for STEMI) randomized
control trial (NCT01740479) aims to further inform on
several of these questions in a cohort of 3,900
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recruited to date. At the present time, our decisions
are made on partial and sometimes contradictory
data, but efforts such as the CvLPRIT CMR substudy
are essential in helping move the ﬁeld forward.
As our understanding of acute coronary syndromes
improves alongside technical success rates in percu-
taneous intervention, we may need to question oldways and embrace new ideas for the beneﬁt of the
patient.
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